ArticleEuropean urology open science2025
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24).
Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cabozantinib After Immunotherapy in Advanced Renal Cell Carcinoma. The CARE Study by the Hellenic Gu Cancer Group.Cancer management and research · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Cabozantinib remains the cornerstone for treatment of patients metastatic renal cell carcinoma (mRCC), whether pretreated with an immune-oncology (IO) agent and/or tyrosine kinase inhibitor, or treatment-naïve but ineligible for IO-based combinations. Methods: CabFRONT (Meet-URO 24) was a retrospective, observational, multicentre study of a real-life population of treatment-naïve patients with intermediate-risk or poor-risk mRCC treated with cabozantinib. Key findings and limitations: A total of 211 treatment- naïve patients with intermediate- or poor-risk mRCC according to the International Metastatic RCC Database Consortium criteria were included. At median follow-up of 50.4 mo (interquartile range 46.9-53.2), median progression-free survival (PFS) was 9.1 mo (interquartile range 7.4-10.4) and median overall survival (OS) was 19.8 mo (95% confidence interval [CI] 14.1-27.0). A reduced dose was not associated with significant differences in median OS (hazard ratio [HR] 1.08, 95% CI 0.77-1.52; Conclusions and clinical implications: Front-line cabozantinib was effective and safe in an unselected real-life population of patients with intermediate-risk or poor-risk mRCC. Cabozantinib could be a choice for patients who cannot receive IO-based combinations or a speculative option for individuals with "early progression" on adjuvant IO. Patient summary: We looked at outcomes for patients with metastatic kidney cancer treated with an inhibitor called cabozantinib in a large European population. We found that cabozantinib is active and safe, and that changes in the dose or treatment schedule because of side effects do not affect outcomes. Cabozantinib could be an option for patients who cannot receive immunotherapy for metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.